Huadong Medicine Co (SZSE:000963) Net Income From Continuing Operations : ¥2,846 Mil (TTM As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Huadong Medicine Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Huadong Medicine Co's net income from continuing operations for the three months ended in Dec. 2023 was ¥653 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was ¥2,846 Mil.

Huadong Medicine Co Net Income From Continuing Operations Historical Data

The historical data trend for Huadong Medicine Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Huadong Medicine Co Net Income From Continuing Operations Chart

Huadong Medicine Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

2,925.40

2,909.72

2,338.63

2,532.63

2,846.40

Huadong Medicine Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Income From Continuing Operations	Get a 7-Day Free Trial															526.30	759.93	679.93	753.69	652.85

Huadong Medicine Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥2,846 Mil.

Huadong Medicine Co (SZSE:000963) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Huadong Medicine Co Ltd (SZSE:000963) » Definitions » Net Income From Continuing Operations

Traded in Other Exchanges

N/A

Address

468 Yan’an Road, Floor 7, 9 and 10, Gate No. 1, Building No. 1, Hangzhou, CHN, 310006

Website

http://www.eastchinapharm.com

Huadong Medicine Co Ltd is engaged in the production and sales of antibiotics, proprietary Chinese medicine, chemical synthetic medicine and genetic engineering drugs products. It is also engaged in the wholesale, retail and distribution business of Chinese and western medicine, Chinese herbal medicine, medical apparatus, and instruments. The main business of the company is divided into pharmaceutical business sales and the industry of pharmaceutical. The product portfolio of the company includes Corbrin capsule, Cymusi, New Cyspin, Kasiping, Panlisu, Acarbose, and others.

Huadong Medicine Co (SZSE:000963) Headlines

No Headlines